Logo

Waters: Christopher O'Connell

Jun 18, 2020

Christopher O'Connell will step down as president, CEO, and a member of the board of directors of Waters, the firm announced this week. Waters said that it has hired an executive search firm to identify a new CEO and that O'Connell will serve as an advisor until the end of this year to support the transition. O'Connell has served as president and CEO of Waters for the past five years, succeeding the firm's long-time leader Doug Berthiaume. According to terms of O'Connell's separation agreement, he will receive a cash severance in the amount of $4,252,500, payable over a two-year period following termination of employment and a bonus for calendar year 2020 based on the company's performance.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.